94 related articles for article (PubMed ID: 9570976)
21. Estrogen plus progestin and the risk of peripheral arterial disease: the Women's Health Initiative.
Hsia J; Criqui MH; Rodabough RJ; Langer RD; Resnick HE; Phillips LS; Allison M; Bonds DE; Masaki K; Caralis P; Kotchen JM;
Circulation; 2004 Feb; 109(5):620-6. PubMed ID: 14769684
[TBL] [Abstract][Full Text] [Related]
22. Comparative cardiovascular effects of different progestins in menopause.
Rosano GM; Fini M
Int J Fertil Womens Med; 2001; 46(5):248-56. PubMed ID: 11720197
[TBL] [Abstract][Full Text] [Related]
23. Use of menopausal hormones in the United States, 1992 through June, 2003.
Wysowski DK; Governale LA
Pharmacoepidemiol Drug Saf; 2005 Mar; 14(3):171-6. PubMed ID: 15386701
[TBL] [Abstract][Full Text] [Related]
24. Age related trends in the incidence of endometrial cancer in South East England 1962-1997.
Somoye G; Olaitan A; Mocroft A; Jacobs I
J Obstet Gynaecol; 2005 Jan; 25(1):35-8. PubMed ID: 16147691
[TBL] [Abstract][Full Text] [Related]
25. Use of HRT and the subsequent risk of cancer.
Beral V; Banks E; Reeves G; Appleby P
J Epidemiol Biostat; 1999; 4(3):191-210; discussion 210-5. PubMed ID: 10695959
[TBL] [Abstract][Full Text] [Related]
26. Hormone replacement therapy and risk of breast cancer: the role of progestins.
Stahlberg C; Pedersen AT; Lynge E; Ottesen B
Acta Obstet Gynecol Scand; 2003 Apr; 82(4):335-44. PubMed ID: 12716318
[TBL] [Abstract][Full Text] [Related]
27. Self-reported stress and risk of endometrial cancer: a prospective cohort study.
Nielsen NR; Strandberg-Larsen K; Grønbaek M; Kristensen TS; Schnohr P; Zhang ZF
Psychosom Med; 2007 May; 69(4):383-9. PubMed ID: 17470667
[TBL] [Abstract][Full Text] [Related]
28. I have recently started taking Prempro (0.625 mg conjugated estrogens/2.5 mg medroxyprogesterone acetate). There is so much written about the benefits of taking estrogen, but I am wondering about the effects of the progesterone component. Will it counteract the benefits of estrogen?
Robb-Nicholson C
Harv Womens Health Watch; 1999 Jan; 6(5):8. PubMed ID: 9916577
[No Abstract] [Full Text] [Related]
29. Post-treatment change in serum estrone predicts mammographic percent density changes in women who received combination estrogen and progestin in the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial.
Ursin G; Palla SL; Reboussin BA; Slone S; Wasilauskas C; Pike MC; Greendale GA
J Clin Oncol; 2004 Jul; 22(14):2842-8. PubMed ID: 15254051
[TBL] [Abstract][Full Text] [Related]
30. HRT dosing regimens: continuous versus cyclic-pros and cons.
Shoupe D
Int J Fertil Womens Med; 2001; 46(1):7-15. PubMed ID: 11294619
[TBL] [Abstract][Full Text] [Related]
31. Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women's Health Initiative randomized controlled trial.
Shapiro S
Climacteric; 2003 Dec; 6(4):302-10; discussion 310-3. PubMed ID: 15006251
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the proliferative effects of estradiol and conjugated equine estrogens on human breast cancer cells and impact of continuous combined progestogen addition.
Mueck AO; Seeger H; Wallwiener D
Climacteric; 2003 Sep; 6(3):221-7. PubMed ID: 14567770
[TBL] [Abstract][Full Text] [Related]
33. Endometrial cancer and exogenous estrogens.
Obrink A; Bunne G; Collen J; Tjernberg B
Acta Obstet Gynecol Scand; 1979; 58(1):123. PubMed ID: 217227
[TBL] [Abstract][Full Text] [Related]
34. Cyclic hormone therapy in climacteric and menopausal women in Iran. Report of 600 cases.
Taleghany P
Int Surg; 1971 Aug; 56(2):78-81. PubMed ID: 4327046
[No Abstract] [Full Text] [Related]
35. Estrogen use and endometrial cancer.
Stolley PD; Davies JL
N Engl J Med; 1979 Apr; 300(16):923. PubMed ID: 218103
[No Abstract] [Full Text] [Related]
36. The prevention of endometrial cancer in postmenopausal women with progestogens.
Gambrell RD
Maturitas; 1978 Sep; 1(2):107-12. PubMed ID: 755956
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of a formulary switch from conjugated to esterified estrogens in a managed care setting.
Andrade SE; Gurwitz JH; Cernieux J; Fish LS
Med Care; 2000 Sep; 38(9):970-5. PubMed ID: 10982118
[TBL] [Abstract][Full Text] [Related]
38. Endometrial cancer risk after discontinuing use of unopposed conjugated estrogens (California, United States).
Finkle WD; Greenland S; Miettinen OS; Ziel HK
Cancer Causes Control; 1995 Mar; 6(2):99-102. PubMed ID: 7749058
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of hormone replacement therapy in the menopause.
Weinstein MC; Schiff I
Obstet Gynecol Surv; 1983 Aug; 38(8):445-55. PubMed ID: 6310460
[TBL] [Abstract][Full Text] [Related]
40. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study.
Persson I; Adami HO; Bergkvist L; Lindgren A; Pettersson B; Hoover R; Schairer C
BMJ; 1989 Jan; 298(6667):147-51. PubMed ID: 2538173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
